UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 1-32001 APTOSE BIOSCIENCES INC. (Exact Name of Registrant as Specified in Its Charter) Canada (State or other jurisdiction of incorporatio ...

Financial Performance - Aptose reported a net loss of $6.95 million for Q3 2024, a decrease of $4.5 million compared to a net loss of $11.45 million in Q3 2023[9]. - Research and development expenses for Q3 2024 were $4.7 million, down from $8.3 million in Q3 2023, reflecting a decrease of $3.6 million[11]. - Total cash and cash equivalents as of September 30, 2024, were $8 million, providing sufficient resources to fund operations through January 2025[10]. - The accumulated deficit as of September 30, 2024, was $539.4 million, compared to $515.5 million at the end of 2023[10]. Clinical Development - Tuspetinib demonstrated broad clinical activity in AML patients during the APTIVATE trial, achieving responses in patients with diverse mutation profiles, including those with adverse genetics[3]. - The company plans to initiate dosing of the TUS+VEN+AZA triplet therapy in newly diagnosed AML patients in Q4 2024[7]. - Program costs for tuspetinib were $4.1 million for Q3 2024, down from $5.8 million in Q3 2023, primarily due to reduced clinical trial activity[12]. - Aptose is negotiating a new co-development collaboration agreement with Hanmi to accelerate the clinical development of tuspetinib[3]. - The company is focused on clinical development plans and the therapeutic potential of tuspetinib[15]. - The progress of clinical trials is a key factor influencing future performance[16]. - The company is exploring partnerships to enhance its clinical development efforts[16]. Compliance and Regulatory Issues - The company is addressing compliance issues with Nasdaq regarding stockholders' equity and minimum bid price requirements[6]. - The company is working on a compliance plan to regain Nasdaq compliance[15]. - There are risks associated with early-stage drug development, including demonstrating efficacy and regulatory approval processes[16]. Capital and Funding - The company is actively seeking capital to fund its research and operations[16]. - The company received a $10 million loan from Hanmi Pharmaceutical to support the development of tuspetinib, convertible into milestone obligations under a future collaboration agreement[3]. Forward-Looking Statements - The company does not intend to update forward-looking statements unless required by law[17]. - Investors are cautioned that forward-looking statements are not guarantees of future performance[17]. Market Conditions - There are uncertainties related to market and economic conditions that could impact results[16]. - The company aims to attract and retain key personnel for its operations[16].

SAN DIEGO and TORONTO, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced financial results for the three months ended September 30, 2024, and provided a corporate update. "Triple drug therapies (triplets) that build on the standard of care in AML have yielded higher response rates yet are limited to ...

Core Viewpoint - Aptose Biosciences Inc. held a special meeting of shareholders on September 5, 2024, where key proposals regarding the issuance of common shares and potential adjournments were approved by the requisite number of votes [1]. Proposal Summary - Proposal No. 1: Approval of the issuance of common shares underlying certain warrants was passed with 3,969,105 votes in favor, representing 93.34% of the votes cast [3]. - Proposal No. 2: Approval for one or more adjournments of the meeting was also passed, with 97.05% of votes in favor [3]. Voting Results - A total of 6,052,460 common shares were voted, accounting for 33.42% of the issued and outstanding shares [1][3]. - The breakdown of votes for Proposal No. 1 included 3,969,105 votes for, 267,013 against, and 16,342 withheld/abstained [3]. - The total shares issued and outstanding were reported as 18,109,393, with 1,800,000 shares held by insiders excluded from the voting results [3]. Company Overview - Aptose Biosciences is a clinical-stage biotechnology company focused on developing precision medicines for oncology, particularly in hematology [4]. - The lead compound, tuspetinib, is an oral kinase inhibitor targeting acute myeloid leukemia (AML) and is being developed for both monotherapy and combination therapy [4].

Core Insights - Aptose Biosciences Inc. has secured a $10 million loan from Hanmi Pharmaceutical Co. Ltd. to support the development of tuspetinib, an oral kinase inhibitor for acute myeloid leukemia (AML) [1][2] - The loan can be converted into prepayment of milestone obligations or repaid after the completion of a triple drug combination trial with tuspetinib in newly diagnosed AML patients [1] - Aptose and Hanmi are negotiating a new co-development collaboration agreement to provide additional funding for the clinical development of tuspetinib [2] Company Overview - Aptose Biosciences is a clinical-stage biotechnology company focused on developing precision medicines for oncology, particularly in hematology [3] - The company's lead compound, tuspetinib, has shown efficacy as both a monotherapy and in combination therapy for relapsed or refractory AML, and is being developed as a frontline triplet therapy for newly diagnosed AML [3]

SAN DIEGO and TORONTO, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced that its special meeting of shareholders (the "Meeting") convened on August 15, 2024, at 1:00 p.m. (ET) has been adjourned to September 5, 2024 at 1 p.m. (ET), without business being considered, due to a lack of quorum. At the t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 1-32001 APTOSE BIOSCIENCES INC. (Exact Name of Registrant as Specified in Its Charter) Canada (State or other jurisdiction of incorporation or ...

EXHIBIT 99.1 Aptose Reports Results for the Second Quarter 2024 TUS+VEN+HMA Triplet Protocol in Frontline Therapy for Newly Diagnosed AML was Reviewed by the FDA and Allowed to Proceed Abstract Supporting Exploration of the TUS+VEN+AZA Triplet in Frontline Therapy for Newly Diagnosed AML has been Submitted to the 2025 Annual Meeting of the American Society of Hematology (ASH) SAN DIEGO and TORONTO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ: APTO, TSX: APS) ...

Table of Contents As filed with the Securities and Exchange Commission on August 1, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 APTOSE BIOSCIENCES INC. (Exact Name of Registrant As Specified In Its Charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Canada 2836 98-1136802 Classification Code Number) (I.R.S. Employer Identification Number) 66 ...

SAN DIEGO and TORONTO, June 18, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced the voting results from the Company's annual and special meeting of shareholders held today, June 18, 2024 (the "Meeting"). A total of 8,101,527 common shares of the Company, representing 49.67% of the common shares of the Compa ...